Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Income (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Non Operating Income for 11 consecutive years, with -$30.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 247.57% year-over-year to -$30.2 million, compared with a TTM value of $29.5 million through Dec 2025, up 151.72%, and an annual FY2025 reading of $29.5 million, up 4818.03% over the prior year.
  • Non Operating Income was -$30.2 million for Q4 2025 at Spyre Therapeutics, down from $45.7 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $45.7 million in Q3 2025 and bottomed at -$98.8 million in Q4 2023.
  • Average Non Operating Income over 5 years is -$2.7 million, with a median of $15500.0 recorded in 2021.
  • The sharpest move saw Non Operating Income plummeted 26230.95% in 2023, then soared 66475.0% in 2024.
  • Year by year, Non Operating Income stood at $19000.0 in 2021, then skyrocketed by 1889.47% to $378000.0 in 2022, then tumbled by 26230.95% to -$98.8 million in 2023, then soared by 120.75% to $20.5 million in 2024, then plummeted by 247.57% to -$30.2 million in 2025.
  • Business Quant data shows Non Operating Income for SYRE at -$30.2 million in Q4 2025, $45.7 million in Q3 2025, and $5.2 million in Q2 2025.